Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study

References

• ConnorsLHDorosGSamFBadieeASeldinDCSkinnerMClinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathyAmyloid201118Suppl 115715921838471
   PubMedGoogle Scholar
• PomeranceASenile cardiac amyloidosisBr Heart J19652757117185829755
   PubMedGoogle Scholar
• PolimantiRDi GirolamoMManfellottoDFuciarelliMIn silico analysis of TTR gene (coding and non-coding regions, and interactive network) and its implications in transthyretin-related amyloidosisAmyloid201421315416224779883
   PubMed Web of Science ®Google Scholar
• CornwellGG3rdMurdochWLKyleRAWestermarkPPitkänenPFrequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlationAm J Med19837546186236624768
   PubMed Web of Science ®Google Scholar
• PinneyJHWhelanCJPetrieASenile systemic amyloidosis: clinical features at presentation and outcomeJ Am Heart Assoc201322e00009823608605
   PubMed Web of Science ®Google Scholar
• LonghiSGuidalottiPLQuartaCCIdentification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphyJACC Cardio-vasc Imaging201475531532
   Web of Science ®Google Scholar
• MohtyDDamyTCosnayPCardiac amyloidosis: updates in diagnosis and managementArch Cardiovasc Dis20131061052854024070600
   PubMed Web of Science ®Google Scholar
• RubergFLMaurerMSJudgeDPProspective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)Am Heart J20121642222228.e122877808
   PubMed Web of Science ®Google Scholar
• BieschkeJRussJFriedrichRPEGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicityProc Natl Acad Sci U S A2010107177710771520385841
   PubMed Web of Science ®Google Scholar
• EhrnhoeferDEBieschkeJBoeddrichAEGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomersNat Struct Mol Biol200815655856618511942
   PubMed Web of Science ®Google Scholar
• FerreiraNCardosoIDominguesMRBinding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicityFEBS Lett2009583223569357619861125
   PubMed Web of Science ®Google Scholar
• FerreiraNSaraivaMJAlmeidaMREpigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: “in vivo” evidence from FAP mice modelsPLoS One201271e2993322253829
   PubMed Web of Science ®Google Scholar
• KristenAVLehrkeSBussSGreen tea halts progression of cardiac transthyretin amyloidosis: an observational reportClin Res Cardiol20121011080581322584381
   PubMed Web of Science ®Google Scholar
• HunsteinWEpigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?Blood20071106221617785589
   PubMed Web of Science ®Google Scholar
• BensonMDTeagueSDKovacsRFeigenbaumHJungJKincaidJCRate of progression of transthyretin amyloidosisAm J Cardiol2011108228528921550574
   PubMed Web of Science ®Google Scholar
• OgawaHSenile cardiac amyloidosis in senescence accelerated mouse (SAM)Jpn Circ J19885212137713833241319
   PubMedGoogle Scholar
• RapezziCMerliniGQuartaCCSystemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main typesCirculation2009120131203121219752327
   PubMed Web of Science ®Google Scholar
• KhuranaSVenkataramanKHollingsworthAPicheMTaiTCPolyphenols: benefits to the cardiovascular system in health and in agingNutrients20135103779382724077237
   PubMed Web of Science ®Google Scholar
• SarmaDNBarrettMLChavezMLSafety of green tea extracts: a systematic review by the US PharmacopeiaDrug Saf200831646948418484782
   PubMed Web of Science ®Google Scholar
• ObiciLMerliniGAn overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosisExpert Opin Investig Drugs201423912391251
   PubMed Web of Science ®Google Scholar
• KeskeMANgHLPremilovacDVascular and metabolic actions of the green tea polyphenol epigallocatechin gallateCurr Med Chem2015221596925312214
   PubMed Web of Science ®Google Scholar
• ChungJHKimSLeeSJChungJOOhYJShimSMGreen tea formulations with vitamin C and xylitol on enhanced intestinal transport of green tea catechinsJ Food Sci2013785C685C69023551173
   PubMed Web of Science ®Google Scholar
• PetersCMGreenRJJanleEMFerruzziMGFormulation with ascorbic acid and sucrose modulates catechin bioavailability from green teaFood Res Int20104319510220161530
   PubMed Web of Science ®Google Scholar
• MerelesDBussSJHardtSEHunsteinWKatusHAEffects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosisClin Res Cardiol201099848349020221615
   PubMed Web of Science ®Google Scholar
• PerdrixLMansencalNCocheteuxBHow to calculate left ventricular mass in routine practice? An echocardiographic versus cardiac magnetic resonance studyArch Cardiovasc Dis2011104534335121693371
   PubMed Web of Science ®Google Scholar
• BellengerNGBurgessMIRaySGComparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?Eur Heart J200021161387139610952828
   PubMed Web of Science ®Google Scholar
• BellengerNGDaviesLCFrancisJMCoatsAJPennellDJReduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonanceJ Cardiovasc Magn Reson20002427127811545126
   PubMed Web of Science ®Google Scholar
• BulawaCEConnellySDevitMTafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProc Natl Acad Sci U S A2012109249629963422645360
   PubMed Web of Science ®Google Scholar
• CoelhoTMaiaLFMartins da SilvaATafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trialNeurology201279878579222843282
   PubMed Web of Science ®Google Scholar
• MerkiesISTafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trialNeurology201380151444144523569001
   PubMed Web of Science ®Google Scholar
• UedaMAndoYRecent advances in transthyretin amyloidosis therapyTransl Neurodegener201431925228988
   PubMedGoogle Scholar
• BrooksJKramerCMSalernoMMarkedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T1 mappingJ Magn Reson Imaging20133861591159523450747
   PubMed Web of Science ®Google Scholar
• FontanaMBanypersadSMTreibelTANative T1 mapping in transthyretin amyloidosisJACC Cardiovasc Imaging20147215716524412190
   PubMed Web of Science ®Google Scholar
• KaramitsosTDPiechnikSKBanypersadSMNoncontrast T1 mapping for the diagnosis of cardiac amyloidosisJACC Cardiovasc Imaging20136448849723498672
   PubMed Web of Science ®Google Scholar
• MaceiraAMPrasadSKHawkinsPNRoughtonMPennellDJCardiovascular magnetic resonance and prognosis in cardiac amyloidosisJ Cardiovasc Magn Reson2008105419032744
   PubMed Web of Science ®Google Scholar
• aus dem SiepenFBussSJAndreFExtracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center studyClin Res Cardiol2015104864064725855392
   PubMed Web of Science ®Google Scholar